James F Sanchez
Overview
Explore the profile of James F Sanchez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1612
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Khalife J, Sanchez J, Pichiorri F
Front Oncol
. 2021 Jul;
11:689538.
PMID: 34235082
Multiple myeloma (MM) is a cancer of terminally differentiated plasma cells (PCs) that develop at multiple sites within the bone marrow (BM). MM is treatable but rarely curable because of...
12.
Zuro D, Madabushi S, Brooks J, Chen B, Goud J, Salhotra A, et al.
Int J Radiat Oncol Biol Phys
. 2021 Jun;
111(3):671-683.
PMID: 34119592
Purpose: Total marrow irradiation (TMI) has significantly advanced radiation conditioning for hematopoietic cell transplantation in hematologic malignancies by reducing conditioning-induced toxicities and improving survival outcomes in relapsed/refractory patients. However, the...
13.
Ghose J, Dona A, Murtadha M, Gunes E, Caserta E, Yoo J, et al.
Mol Ther Oncolytics
. 2021 Mar;
20:519-531.
PMID: 33738338
Because most patients with multiple myeloma (MM) develop resistance to current regimens, novel approaches are needed. Genetically modified, replication-competent oncolytic viruses exhibit high tropism for tumor cells regardless of cancer...
14.
Khalife J, Sanchez J, Pichiorri F
Diagnostics (Basel)
. 2020 Dec;
10(12).
PMID: 33316884
Small extracellular vesicles (EVs) are a heterogenous group of lipid particles released by all cell types in physiological and pathological states. In hematological malignancies, tumor-derived EVs are critical players in...
15.
Krishnan A, Adhikarla V, Poku E, Palmer J, Chaudhry A, Biglang-Awa V, et al.
Blood Adv
. 2020 Oct;
4(20):5194-5202.
PMID: 33095874
18F-Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is one of the most widely used imaging techniques to detect multiple myeloma (MM). Intracellular FDG uptake depicts in vivo metabolic activity, which...
16.
Nathwani N, Palmer J, Synold T, Salehian B, Rosenzweig M, Sanchez J, et al.
Clin Lymphoma Myeloma Leuk
. 2020 Jul;
20(10):e667-e672.
PMID: 32631779
No abstract available.
17.
Viola D, Dona A, Caserta E, Troadec E, Besi F, McDonald T, et al.
Leukemia
. 2020 Apr;
35(1):189-200.
PMID: 32296125
Daratumumab (Dara), a multiple myeloma (MM) therapy, is an antibody against the surface receptor CD38, which is expressed not only on plasma cells but also on NK cells and monocytes....
18.
Rosenzweig M, Palmer J, Tsai N, Synold T, Wu X, Tao S, et al.
Leuk Lymphoma
. 2020 Apr;
61(7):1669-1677.
PMID: 32268821
The inexpensive, well-tolerated, immunomodulatory agent leflunomide, used extensively for the treatment of rheumatoid arthritis, has been shown to produce significant activity against multiple myeloma (MM) in pre-clinical studies. We conducted...
19.
Krishnan A, Kapoor P, Palmer J, Tsai N, Kumar S, Lonial S, et al.
Leukemia
. 2020 Feb;
32(7):1567-1574.
PMID: 32082000
In this phase I/II trial, a triplet regimen of ixazomib (Ixa: 3 or 4 mg), pomalidomide (Pom: 4 mg), and dexamethasone (Dex: 40 mg) was administered to 32 lenalidomide-refractory multiple...
20.
Khalife J, Ghose J, Martella M, Viola D, Rocci A, Troadec E, et al.
JCI Insight
. 2019 Oct;
4(21).
PMID: 31593552
High levels of circulating miR-16 in the serum of multiple myeloma (MM) patients are independently associated with longer survival. Although the tumor suppressor function of intracellular miR-16 in MM plasma...